Back to Archived News
Stem Cell Therapeutics Announces Issuance of Additional Patent
Tuesday, January 08, 2008
SCT is granted intellectual property protection in Australia
Calgary, Alberta -- Stem Cell Therapeutics Corp. ("SCT") (TSX Venture:SSS) is pleased to announce that the Company's strong intellectual property portfolio has been enhanced by the addition of a new patent granted in Australia.
This Australian patent, numbered 2002325712 and entitled "Differentiation of Neural Stem Cells and Therapeutic Use Thereof", protects the combination of prolactin with agents such as erythropoietin (EPO) or pituitary adenylate cyclase activating polypeptide (PACAP) for treating patients suffering from a variety of central nervous system (CNS) disorders including brain injury, stroke, Alzheimer's disease, multiple sclerosis (MS), Huntington's disease, amyotrophic lateral sclerosis, Parkinson's disease, and other CNS diseases. The strategy of using a therapeutic regimen of drugs to produce neuronal or glial precursor cells, as taught in this patent, has the potential to be a key treatment for many CNS diseases.
"We are very pleased with the issuance of this patent in Australia as it expands our international intellectual property coverage for this patent family, adding to patents previously issued in the US and Japan" said Dr. Alan Moore, President and CEO of SCT. "Our strong international patent position provides us with a significant market advantage and incentive to widen our therapeutic scope initially focused on NTxTM-265. As such, we are now assessing the efficacy of a Prolactin-EPO regimen versus an hCG-EPO regimen in a pre-clinical model of traumatic brain injury."
AboutNTxTM-265
NTxTM-265 is a therapeutic regimen of two approved and clinically well-defined drugs, human Chorionic Gonadotropin (hCG) and Erythropoietin (EPO), targeting the treatment of stroke. The objective of the regimen is to stimulate the growth and differentiation of new neurons to replace the brain cells that were lost or damaged by the stroke. Animal studies have shown a significant recovery in motor function after receiving the NTxTM-265 regimen 24-48 hours post stroke. Similar results have been found in SCT's Phase IIa BETAS safety trial, as announced on April 10, 2007. Final results of SCT's Phase IIa BETAS trial will be released February 2008 at the International Stroke Conference in New Orleans, LA. SCT has initiated a multi-centre, double-blind, placebo-controlled Phase IIb REGENESIS study for NTxTM-265 with primary endpoints of efficacy.
About Stem Cell Therapeutics Corp.
Stem Cell Therapeutics Corp. is a Canadian public biotechnology company (TSX Venture: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The company's programs aim to repair neurological function lost due to disease or injury. The company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases.
For further information on Stem Cell Therapeutics Corp., visit www.stemcellthera.com.
These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.
Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
Back to Archived News
